O Barkay1, E Niv, E Santo, R Bruck, A Hallak, F M Konikoff. 1. Department of Gastroenterology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel. olgabi@netvision.net.il
Abstract
BACKGROUND: As suggested by observational and animal studies, heparin has antiinflammatory effects that could prevent acute post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Low-molecular-weight heparin did not reduce the incidence of post-ERCP pancreatitis in a controlled study. The current study aimed to determine whether prophylactic administration of low-dose unfractionated heparin, which has potentially more antiinflammatory capability, can prevent acute post-ERCP pancreatitis. METHODS:Patients scheduled for ERCP in the authors' department were randomized to receive unfractionated heparin (5,000 IU) or placebo (saline solution 0.5 ml) administered subcutaneously 20 to 30 min before the ERCP. Patients who had undergone endoscopic sphincterotomy in the past were excluded from the study. Post-ERCP pancreatitis was defined according to criteria established by Cotton: abdominal pain combined with a threefold elevation of blood amylase 24 h after the ERCP. RESULTS: The study enrolled 106 patients. One patient was excluded from the analysis due to inaccessible papilla of Vater, leaving 51 patients in the heparingroup and 54 in the placebo group, for a total of 105 patients (62 women and 43 men) with a mean age of 64.6 years. The rate of post-ERCP pancreatitis was not different between the groups (heparin, 4 patients, 7.8%; placebo, 4 patients, 7.4%). Two patients in each group experienced mild bleeding. CONCLUSIONS: The study did not demonstrate a significant effect of low-dose unfractionated heparin in the prevention of post-ERCP pancreatitis. A multicenter trial with a larger number of patients is needed to demonstrate a benefit from this drug.
RCT Entities:
BACKGROUND: As suggested by observational and animal studies, heparin has antiinflammatory effects that could prevent acute post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Low-molecular-weight heparin did not reduce the incidence of post-ERCP pancreatitis in a controlled study. The current study aimed to determine whether prophylactic administration of low-dose unfractionated heparin, which has potentially more antiinflammatory capability, can prevent acute post-ERCP pancreatitis. METHODS:Patients scheduled for ERCP in the authors' department were randomized to receive unfractionated heparin (5,000 IU) or placebo (saline solution 0.5 ml) administered subcutaneously 20 to 30 min before the ERCP. Patients who had undergone endoscopic sphincterotomy in the past were excluded from the study. Post-ERCP pancreatitis was defined according to criteria established by Cotton: abdominal pain combined with a threefold elevation of blood amylase 24 h after the ERCP. RESULTS: The study enrolled 106 patients. One patient was excluded from the analysis due to inaccessible papilla of Vater, leaving 51 patients in the heparin group and 54 in the placebo group, for a total of 105 patients (62 women and 43 men) with a mean age of 64.6 years. The rate of post-ERCP pancreatitis was not different between the groups (heparin, 4 patients, 7.8%; placebo, 4 patients, 7.4%). Two patients in each group experienced mild bleeding. CONCLUSIONS: The study did not demonstrate a significant effect of low-dose unfractionated heparin in the prevention of post-ERCP pancreatitis. A multicenter trial with a larger number of patients is needed to demonstrate a benefit from this drug.
Authors: J Devière; O Le Moine; J L Van Laethem; P Eisendrath; A Ghilain; N Severs; M Cohard Journal: Gastroenterology Date: 2001-02 Impact factor: 22.682
Authors: Elham Afghani; Stephen J Pandol; Tooru Shimosegawa; Robert Sutton; Bechien U Wu; Santhi Swaroop Vege; Fred Gorelick; Morihisa Hirota; John Windsor; Simon K Lo; Martin L Freeman; Markus M Lerch; Yoshihisa Tsuji; Gil Y Melmed; Wahid Wassef; Julia Mayerle Journal: Pancreas Date: 2015-11 Impact factor: 3.327
Authors: Fariborz Mansour-Ghanaei; Farahnaz Joukar; Ali Akbar Khalesi; Mohammadreza Naghipour; Masood Sepehrimanesh; Kourosh Mojtahedi; Sara Yeganeh; Hamid Saeidi Saedi; Saba Fakhrieh Asl Journal: Ann Hepatobiliary Pancreat Surg Date: 2020-08-31
Authors: Gabriele Fluhr; Julia Mayerle; Eckhard Weber; Ali Aghdassi; Peter Simon; Thomas Gress; Thomas Seufferlein; Joachim Mössner; Andreas Stallmach; Thomas Rösch; Martina Müller; Britta Siegmund; Petra Büchner-Steudel; Ina Zuber-Jerger; Marcus Kantowski; Albrecht Hoffmeister; Jonas Rosendahl; Thomas Linhart; Jochen Maul; László Czakó; Péter Hegyi; Matthias Kraft; Georg Engel; Thomas Kohlmann; Anne Glitsch; Tilman Pickartz; Christoph Budde; Claudia Nitsche; Kirsten Storck; Markus M Lerch Journal: BMC Gastroenterol Date: 2013-01-15 Impact factor: 3.067